advances in psma radioligand therapy for mcrpc
Published 2 years ago • 211 plays • Length 4:47Download video MP4
Download video MP3
Similar videos
-
1:36
advances in psma-targeted therapy for prostate cancer
-
2:45
arrow: psma-targeted radioligand therapy plus enzalutamide in mcrpc
-
2:18
radioligand therapy for mcrpc
-
2:04
radioligand therapy advancements in prostate cancer
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
0:44
remaining questions regarding psma radioligand therapies
-
4:48
vision: lu-177-psma-617 in mcrpc
-
1:38
177lu-psma i&t for patients with psma-positive mcrpc
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
3:30
radionuclide conjugates 225ac-j591 and 177lu-psma-i&t for mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
1:49
radioligands in the future of prostate cancer treatment
-
2:56
psma pet ratio predicts response to [177lu]psma radioligand therapy: a multicenter study
-
3:53
upcoming advances in prostate cancer: parpi, cdk4/6, lutetium psma therapy & car-t approaches
-
2:10
integrating radioligand therapy for prostate cancer in us clinical practice
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc